There are several population programs going on in genomics across the world which are trying to understand the genetic variants, the variations in even the common diseases which can help individuals in prevention of chronic diseases. 

It will evolve in the next 6 to7 years as the pharma companies will come up with more cost-effective treatments. In the years ahead genomics will transform the treatments of more common diseases like heart diseases and hypertension.

Dr. Vedam Ramprasad, CEO, Medgenome said that the common thing we have to identify is the genetic basis, you can mimic them in the sort of drugs and this is going to become more common as we see more data connected with both phenotypic parameters, more clinical parameters, traits and diseases. 

He said the challenge lies in identifying those risk variants at an extremely low cost and come up with a scope to tell an individual that he is predisposed or at a higher risk of an early heart attack this is such a big problem in etymology in India. 

He shared the concept of polygenic risk scores. It is a binomial distribution that in any population you take there are 5 per cent of individuals who are resistant to any common disease and 5 per cent are at higher risk. Watch Dr Vedam Ramprasad, CEO, Medgenome, decipher genomics from its merits to its pitfalls.